eClinical Technology and Industy News

Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer

Excerpt from the Press Release:

  • Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported in vitro and in vivo preclinical data demonstrating the potent dual mechanistic activity of TPST-1495, an orally-available small molecule designed to block the EP2 and EP4 receptors in the prostaglandin (PGE2) pathway. The data show that TPST-1495 effectively promotes anti-tumor activity through both T cell-dependent and -independent mechanisms. TPST-1495 is currently being evaluated in an ongoing Phase 1a/1b dose and schedule optimization trial in patients with solid tumors.

“We’re happy to present these data that build upon existing significant preclinical support for the hypothesis that selectively targeting the EP2 and EP4 receptors together, to the exclusion of EP1 and EP3, is the preferred approach to modulate the prostaglandin pathway for clinical benefit in cancer,” said Tom Dubensky, president of Tempest. “We look forward to generating clinical data as TPST-1495 moves into a mechanism-based combination study with pembrolizumab this quarter, as well as into expansion studies in targeted patient populations in the first half of 2022.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?